In Beverly Hills, California, on February 6, 2026, Nordicus Partners Corporation (OTCQB: NORD), a financial consulting firm focusing on aiding Nordic and U.S. life sciences companies in penetrating the U.S. market, shared a corporate update. This update included progress reports on its subsidiaries - Oricidin, Bio-Convert, and NoviThera, as well as details on the status of the Company's application to uplist on Nasdaq.